Stocktoria
BioCardia, Inc. BCDA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1996-11-13
BioCardia, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $58,000 | $477,000 | $1.4M | $1.0M |
| R&D expense | $5.0M | $4.4M | $7.7M | $8.8M | $8.6M |
| SG&A expense | $3.3M | $3.7M | $4.4M | $4.4M | $5.1M |
| Operating income | -$8.3M | -$8.0M | -$11.6M | -$11.9M | -$12.6M |
| Interest expense | — | — | — | — | $0 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$8.2M | -$7.9M | -$11.6M | -$11.9M | -$12.6M |
| Operating cash flow | -$7.4M | -$7.9M | -$10.0M | -$10.6M | -$10.4M |
| Free cash flow | -$7.4M | -$7.9M | -$10.0M | -$10.6M | -$10.5M |
| Cash & equivalents | $2.5M | $2.4M | $1.1M | $7.4M | $12.9M |
| Total assets | $3.4M | $3.7M | $3.0M | $9.8M | $15.7M |
| Total liabilities | $2.5M | $2.9M | $4.6M | $4.9M | $5.3M |
| Shareholders' equity | $895,000 | $837,000 | -$1.6M | $4.9M | $10.4M |
Source: SEC EDGAR filings · CIK 0000925741 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.